SecBot SecBot
8-K ·Filed May 13, 2026

TYRA

Tyra Biosciences, Inc.
MIXED
Impact 5/10
Horizonmonths Processed6mo ago SEC0001193125-26-220638
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Pipeline catalysts in 2H 2026 (SURF302 Aug, BEACH301 Q4) are key events. Near-term stock move hinges on clinical data, not financials. Monitor enrollment updates and early efficacy signals.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$36.19
T+0 close · May 13, 2026 · via day close
Latest settled
−26.75%
T+60 · $26.51
Vs SPY
−31.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $36.19entry
  2. T+1 · 6mo ago +0.88%α +0.11% · $36.51
  3. T+5 · 6mo ago −6.66%α −5.50% · $33.78
  4. T+20 · 5mo ago −29.35%α −28.73% · $25.57
  5. T+60 · 3mo ago −26.75%α −31.19% · $26.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R&D spending. Cash and investments stood at $383.5M following a $147.9M ATM raise, extending runway into 2H 2028. Pipeline advancements include first patient dosed in potentially registrational SURF303 study and dose escalation cleared in BEACH301.

Key Financial Metrics

EPS
−$0.64
Revenue
$0.00

Key Facts

  • Q1 2026 net loss per share -$0.64 vs -$0.47 in Q1 2025
  • Cash and marketable securities of $383.5M; runway into 2H 2028
  • Received $147.9M net proceeds from ATM offering (4,690,532 shares)
  • First patient dosed in Phase 2a/b SURF303 study for LG-UTUC; initial results 2027
  • SURF302 initial three-month complete response data expected August 2026 (n>20 enrolled)
  • BEACH301 cleared fourth dose level; safety sentinel cohort results expected Q4 2026

Financial Impact

Net loss widened by 40% YoY; cash position strengthened by $147.9M ATM raise

net_losscash_positiondilution

Risk Factors

  • Clinical trial failure or disappointing data in upcoming readouts
  • Dilution from ATM offering (4.7M shares) may pressure stock
  • Cash burn rate increasing with expanded clinical programs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-220638
Document: tyra-20260513.htm0001193125-26-220638
Document: 0001193125-26-220638-index-headers.html0001193125-26-220638
Document: 0001193125-26-220638-index.html0001193125-26-220638
Document: 0001193125-26-220638.txt0001193125-26-220638
8-K Data (Synthetic)0001193125-26-220638

Track record

13 reports on TYRA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
  2. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
  3. Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
  4. Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
  5. Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
  6. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
  7. Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
  9. May 13, 202626w ago 8-K Mixed 5/10 Viewing Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
  10. Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026